The US Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide), Eli Lilly and Company’s new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) injection, to be used as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes.
Recent clinical trials ALSO found that, while not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators. “The approval of Mounjaro is an exciting step forward for people living with Type 2 diabetes, given the results seen in these clinical trials,” said Juan Pablo Frías, M.D., Medical Director, National Research Institute.
Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is expected to be made available in the US in the coming weeks
To read more, CLICK HERE.
